[Home ] [Archive]   [ فارسی ]  
:: Main :: About :: Current Issue :: Archive :: Search :: Contact ::
Main Menu
Home::
Journal Information::
Articles archive::
For Authors::
For Reviewers::
Subscription::
Contact us::
Site Facilities::
::
Search in website

Advanced Search
Receive site information
Enter your Email in the following box to receive the site news and information.
Last site contents
:: Editorial Board
:: About Iranian Journal of Endocrinology and Metabolism
:: Volume 22, Issue 3 (10-2020) ::
2020, 22(3): 221-229 Back to browse issues page
Safety and Efficacy of Melatonin in the Lipid Profile of Patients with Type 2 Diabetes Mellitus: A Randomized Clinical Trial
Amir Farrokhian , Maryam Tohidi , Mahtab Niroomand , Nooshin Sadat Ahanchi , Davoud Khalili , Arash Darakhshi , Ali Pirsalehi , Farzad Hadaegh , Mohammad Abbasinazari
Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran,
Abstract:   (2369 Views)
Introduction: Melatonin is available as a dietary supplement and is frequently used for sleep disorders. Decrease in cholesterol absorption, increase in LDL oxidation, and decrease in free fatty acids have been associated with melatonin use. The present study aimed to evaluate the effects of melatonin on changes in the lipid profile of patients with type 2 diabetes mellitus. Materials and Methods: This double-blind randomized clinical trial was conducted on patients with diagnosis of type 2 diabetes mellitus. They were allocated to receive either 6 mg/d of melatonin or placebo for a minimum of eight weeks. The levels of cholesterol, triglyceride, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) were evaluated at baseline and at the end of the study. Results: The demographic characteristics, baseline lipid profiles, and current medication use were found to be similar in the two groups, except for metformin use (100% vs. 86.11%; P=0.02). There was no significant difference between the two groups in terms of the lipid parameters, such as cholesterol, triglyceride, LDL, and HDL levels (P=0.26, 0.81, 0.21, and 0.66, respectively). There were no serious adverse drug reactions in the two groups during the study. Conclusion: According to the results of this trial, 6 mg/d of melatonin does not change the lipid profile of patients with type 2 diabetes mellitus.
Keywords: Melatonin, Type 2 diabetes mellitus, Lipid profile, Dietary supplement, Melatonin level
Full-Text [PDF 1087 kb]   (725 Downloads)    
Type of Study: Original | Subject: Endocrinology
Received: 2020/02/10 | Accepted: 2020/11/18 | Published: 2020/10/1
Add your comments about this article
Your username or Email:

CAPTCHA


XML   Persian Abstract   Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Farrokhian A, Tohidi M, Niroomand M, Ahanchi N S, Khalili D, Darakhshi A, et al . Safety and Efficacy of Melatonin in the Lipid Profile of Patients with Type 2 Diabetes Mellitus: A Randomized Clinical Trial. Iranian Journal of Endocrinology and Metabolism 2020; 22 (3) :221-229
URL: http://ijem.sbmu.ac.ir/article-1-2692-en.html


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 22, Issue 3 (10-2020) Back to browse issues page
مجله ی غدد درون‌ریز و متابولیسم ایران، دو ماهنامه  پژوهشی مرکز تحقیقات غدد درون‌ریز و متابولیسم، Iranian Journal of Endocrinology and Metabolism
Persian site map - English site map - Created in 0.19 seconds with 38 queries by YEKTAWEB 4657